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DesCripTion   
Merkel cell carcinoma is a rare, aggressive neuroendo-
crine skin carcinoma.1 Several studies showed utility 
of 18F-Fluorodeoxyglucose (FDG) Positron Emission 
Tomography/Computed Tomography (PET/CT) for 
staging or surveillance of Merkel cell carcinoma,2 but 
few reported imaging with treatment response and 
none for a parotid primary. Treatment depends on 
disease stage, but there is no consensus.3 
We report the first case imaging and showing 
treatment response for a primary parotid Merkel 
cell carcinoma and we emphasise the relevance of a 
chemotherapy type in absence of consensus.
An 87-year-old man was referred to our depart-
ment for the staging of a bulky parotid tumour 
first documented as a lymphoma on cytology. This 
staging showed a voluminous parotid tumour with 
metastatic dissemination. Then, a biopsy of this 
lesion was realised, and showed a poorly differenti-
ated neuroendocrine carcinoma with histology and 
immunohistochemistry consistent with a Merkel 
cell carcinoma. Finally, the patient underwent 
high-dose chemotherapy (carboplatin–etoposide) 
and was readdressed 5 weeks after the last cycle 
to assess the response to treatment. It showed 
excellent partial response of primary tumour and 
complete metabolic response of metastases.
First of all, the patient was referred to our depart-
ment for the staging of a bulky parotid tumour docu-
mented as a lymphoma on cytology. Coronal and 
transaxial images of fused PET/CT, CT and PET 
showed a hypermetabolic bulky lesion centred on the 
parotid region with a SUVmax of 16.8 g/mL (figure 1A, 
arrow and top rows) extending to both sides of the 
right mandibular horizontal branch, and several meta-
static hypermetabolic lymph nodes (SUVmax 6.9 g/mL) 
in region IIA and IIB (figure 1A, bottom rows). The 
18F-FDG PET/CT images also showed bulky lymph 
nodes (figure 1B, arrow) and a contralateral lesion 
(figure 1B) with the presence of two bone lesions: 
one in the vertebral body of C7 (SUVmax 4.5 g/mL) 
(figure 1C, arrow) and another in the right iliac bone 
(SUVmax of 5.5 g/mL) (figure 1D, arrow).
Then, a biopsy was realised on this lesion 
and it actually showed a poorly differentiated 
neuroendocrine carcinoma with histology and 
Figure 1 Imaging of parotid primary Merkel cell 
carcinoma (A) and metastatic locations (B, C and D) 
before chemotherapy.
Figure 2 Imaging of parotid primary Merkel cell 
carcinoma (A) and metastatic locations (B, C and D) after 
chemotherapy.
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immunohistochemistry consistent with a Merkel cell carci-
noma. Since a meticulous full body dermatological examination 
failed to found lesions or arguments for it, since 18F-FDG PET/
CT images did not show cutaneous lesions or arguments for it, 
and since the patient only complained of parotid painless deep 
swelling, we concluded to a primary parotid Merkel cell carci-
noma. The patient underwent high-dose intravenous chemo-
therapy carboplatin/etoposide, and then was re-addressed for a 
2nd18F-FDG PET/CT 5 weeks after the last cycle to assess the 
response to treatment.
After chemotherapy, coronal and transaxial images of PET/
CT fusion, CT and PET showed a drastic regression of the volu-
minous hypermetabolic lesions (figure 2A, arrow and top rows). 
The tumorous burden was much reduced, with only a small 
residual primary parotid lesion (with a SUVmax slight increase to 
19.0 g/mL or +13% from baseline, however) (figure 2A, bottom 
rows). All other images showed a complete metabolic response of 
the lymph nodes and skeletal metastases (figure 2B–D, arrows), 
without new lesion identified.
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Learning points
 ► 18F-FDG PET/CT is useful for diagnosis and therapy 
monitoring of Merkel cell carcinoma.
 ► Be aware that Merkel cell carcinoma and lymphoma can 
have the same aspect on PET/CT imaging and so can be 
confounded.
 ► The origin of Merkel cell carcinoma can be the parotid.
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